Lilly/Galapagos Forge Osteoporosis Drug Collaboration
This article was originally published in The Pink Sheet Daily
Executive Summary
Primary goal for the alliance is an oral, bone-building drug to prevent osteoporosis, Lilly tells “The Pink Sheet” DAILY.
You may also be interested in...
Deals Of The Week: Pfizer Management Updates Thoughts On Split
Pfizer top management hasn’t yet decided whether it will divide in two or stop at a “virtual split.” Plus updates on Lundbeck/Otsuka, Shire/SARcode, AstraZeneca/Actavis, and more.
Galapagos Hits Two Partnership Milestones
Step in osteoporosis deal earns firm €1 million from Lilly.
Galapagos Hits Two Partnership Milestones
Step in osteoporosis deal earns firm €1 million from Lilly.